U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H13N3O3
Molecular Weight 259.2606
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BEMORADAN

SMILES

CC1CC(=O)NN=C1C2=CC3=C(NC(=O)CO3)C=C2

InChI

InChIKey=XZPGINPFWXLYNW-UHFFFAOYSA-N
InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)

HIDE SMILES / InChI
Molecular Formula C13H13N3O3
Molecular Weight 259.2606
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Bemoradan (RWJ-22867), a potent positive inotropic agent, inhibits cardiac phosphodiesterase fraction III. This compound was developed for the management of congestive heart failure. However, the information about the nowadays study of bemoradan is not available.

Originator

Ortho-McNeil
12

Approval Year

Unknown
139,594

PubMed

Patents

05221742
2
JPH0225421A
1

Sample Use Guides

In Vivo Use Guide
bemoradan HCL salt in capsules. 0.5, 1, 1.5 and 2 mg of bemoradan
Route of Administration: Oral
Substance Class Chemical
Record UNII
G2S2V1ETBQ
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966